CoChat
Sign Up
Cited by 177Gastrointestinal motility and disordersParkinson's Disease Mechanisms and TreatmentsPelvic floor disorders treatments

Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study

Zangaglia, Roberta, Martignoni, Emilia, Glorioso, Margaret, Ossola, Maria, Riboldazzi, Giulio, Calandrella, Daniela, Brunetti, Gabriele, Pacchetti, Claudio·2007·Movement Disorders
DOI 10.1002/mds.21243
Open this paper in CoChat — free account

Abstract

Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution for the treatment of constipation in PD patients, in a double-blind, placebo-controlled study. A total of 57 PD patients with constipation were randomly assigned to receive an isosmotic macrogol electrolyte solution (MC-ES; 29 patients) or placebo (28 patients) for 8 weeks. Treatment efficacy was defined as complete relief of the symptom or a marked improvement of two of the following indicators: stool frequency, straining, stool consistency, use of rectal laxatives as a rescue therapy. The responder rates were significantly higher in the MC-ES group both at the first (4 weeks; P < 0.0003) and at the final evaluation (8 weeks; P < 0.0012). The frequency of bowel movements (P < 0.002) and stool consistency (P < 0.006) were significantly changed in the MC-ES group compared to the placebo group. At the final evaluation, a rectal laxative was used by 2 (12.5%) patients on placebo, whereas no use was recorded in the MC-ES group. Responder rate for straining showed a favorable trend in patients treated with macrogol versus placebo. Unified Parkinson's Disease Rating Scale Part III and Parkinson's Disease Questionnaire (PDQ-39) did not show any significant modification in either group during the 8-week…

Integrity signals

Registry

Crossref · 10.1002/mds.21243

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Randomized controlled trials have demonstrated benefit of polyethylene glycol 3350 and lubiprostone in Parkinson disease-related constipation.

    “Randomized controlled trials have demonstrated benefit of polyethylene glycol 3350 (Zangaglia et al., 2007) and lubiprostone (Ondo et al., 2012) in PD-related constipation, and dopaminergic agents such as apomorphine can influence defecatory function (Edwards et al., 1993b).”

    From Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction (2026) · cites this paper as Zangaglia et al., 2007

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Zangaglia, R., Martignoni, E., Glorioso, M., Ossola, M., Riboldazzi, G., Calandrella, D., Brunetti, G., & Pacchetti, C.
Affiliations
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • University of Insubria (IT)
Corresponding author
Zangaglia, Roberta
ORCID
Venue
Movement Disorders
Publisher
Wiley
Published
2007-06-12
Volume
22
Issue
9
Pages
1239-1244
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
DOI
10.1002/mds.21243
OpenAlex
W1966941681
Cited by
177
References
34
Citations by year
2026: 7 · 2025: 12 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 8 · 2018: 10 · 2017: 6 · 2016: 14 · 2015: 14 · 2014: 5 · 2013: 15 · 2012: 10
FWCI
7.18
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Movement Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Rheumatology › Pelvic floor disorders treatments
Keywords
Parkinson's disease, constipation, macrogol, polyethylene glycol electrolyte solution, autonomic dysfunction, stool frequency, stool consistency, straining, treatment efficacy and safety
MeSH terms
Aged, Constipation, Double-Blind Method, Female, Humans, Male, Parkinson Disease, Polyethylene Glycols, Severity of Illness Index, Surface-Active Agents, Time Factors, Chi-Square Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review